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The differential use of CC chemokine receptor 5 (CCR5) and CXC chemokine receptor 4 (CXCR4) may be
intimately involved in the transmission and progression of human immunodeficiency virus infection. Changes
in coreceptor utilization have also been noted upon adaptation of primary isolates (PI) to growth in established
T-cell lines. All of the T-cell line-adapted (TCLA) viruses studied to date utilize CXCR4 but not CCR5. This
observation had been suggested as an explanation for the sensitivity of TCLA, but not PI, viruses to neutral-
ization by recombinant gp120 antisera and V3-directed monoclonal antibodies, but recent studies have shown
coreceptor utilization to be independent of neutralization sensitivity. Here we describe a newly isolated TCLA
virus that is sensitive to neutralization but continues to utilize both CXCR4 and CCR5 for infection. This
finding further divorces coreceptor specificity from neutralization sensitivity and from certain changes in cell
tropism. That the TCLA virus can continue to utilize CCR5 despite the changes that occur upon adaptation and
in the apparent absence of CCR5 expression in the FDA/H9 T-cell line suggests that the interaction between
envelope protein and coreceptor may be mediated by multiple weak interactions along a diffuse surface.
The discovery of cellular molecules that act as coreceptors in
conjunction with CD4 to mediate the binding and entry of
human immunodeficiency virus type 1 (HIV-1) has provided a
new perspective from which to approach questions of HIV-1
biology and pathogenesis. The differential use of CC chemo-
kine receptor 5 (CCR5) and CXC chemokine receptor 4
(CXCR4) by primary isolates of HIV-1 throughout infection
may have important implications for virus transmission and
disease progression. HIV-1 infection first manifests as an acute
viremic episode, typically involving a homogeneous outgrowth
of monocytotropic, non-syncytium-inducing (NSI) viruses (53,
62) that utilize CCR5 as a coreceptor. Although the initial
events in virus transmission are largely inaccessible to analysis,
cells of the monocyte-macrophage lineage are believed to pro-
vide a portal for primary infection and a specific filter for
monocytotropic NSI viruses (20). Persons lacking a functional
CCR5 coreceptor are resistant to the establishment of HIV-1
infection (8, 28, 43).
Viruses that utilize the CXCR4 coreceptor evolve over the
course of infection (61). These T-lymphocytotropic viruses no
longer infect monocyte-derived macrophages (45, 46) but gen-
erally continue to utilize CCR5 in addition to CXCR4 (7).
Endogenous production of CCR5-specific chemokines may
provide the selective pressure for this broadening in coreceptor
use (44). Importantly, the emergence of dual-coreceptor-uti-
lizing syncytium-inducing (SI) viruses in a proportion of in-
fected persons is prognostic for the development of clinical
AIDS (50).
In contrast to primary isolate (PI) viruses, the commonly
used laboratory isolates of HIV-1 utilize only CXCR4 as a
coreceptor (1, 2, 6, 10, 12, 13, 27, 47). These isolates have been
adapted to persistent growth in T-cell lines, and the loss of
their ability to utilize CCR5 is perhaps understandable in that
most T-cell lines express CXCR4 but not CCR5 (1, 15).
Coincident with changes in coreceptor utilization and cell
tropism upon adaptation are changes in neutralization sensi-
tivity. In contrast to PI viruses, T-cell line-adapted (TCLA)
viruses are generally sensitive to neutralization by appropriate
antibodies directed to the third variable loop (V3) of envelope
surface protein gp120 (42, 55). In addition, PI viruses are
entirely refractory to neutralization by recombinant HIV en-
velope protein gp120 (rgp120) antisera that potently neutralize
related TCLA viruses (31, 55, 56). The unique ability of PI
viruses to utilize CCR5 had been suggested as a basis for the
ability of these viruses to escape neutralization, but recent
reports have shown that PI viruses remain refractory to neu-
tralization, regardless of the specific coreceptor utilized (27,
32, 52).
As part of our studies to define the relationship between
changes in coreceptor utilization and virus phenotype, we iso-
lated a TCLA derivative of molecularly cloned SI primary virus
ACH320.2A.1.2 (21, 22). Although the TCLA virus was now
able to infect T-cell lines and was sensitive to antibody-medi-
ated virus neutralization, this virus continued to utilize both
CCR5 and CXCR4 coreceptors. The intact capacity of this
TCLA virus to utilize CCR5 suggests that changes in corecep-
tor utilization are neither associated with changes in neutral-
ization sensitivity nor required for changes in cell tropism.
Adaptation of a molecularly cloned SI primary virus. The
infectious molecularly cloned provirus ACH320.2A.1.2 was
isolated from a biologically cloned SI PI obtained from a mem-
ber of the Amsterdam Cohort 9 weeks after seroconversion
(21, 22). The ACH320.2A.1.2 plasmid was obtained from
Hanneke Schuitemaker (Central Laboratory of the Nether-
lands Red Cross) through the NIBSC AIDS Reagent Project
(United Kingdom). Virus (320SI) was regenerated by electro-
poration and expansion in phytohemagglutinin-activated pe-
ripheral blood lymphocytes (PBLs). Supernatants containing
high levels of 320SI were used in efforts to adapt this PI virus
to growth in an established T-cell line. As in previous studies
(55), we utilized the Food and Drug Administration (FDA)
isolate of the H9 cell line (37) because of its increased ability,
relative to other H9 cell lines, to manifest a cytopathic effect
upon infection. By other measures, FDA/H9 cells behave sim-
ilarly to other H9 cell lines (unpublished data).
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In contrast to our previous experience obtained by using a
biological isolate of another primary SI virus, ACH168.10 (50,
55), several long-term attempts to obtain infection of FDA/H9
cells by 320SI were without success. In an effort to increase the
genetic complexity of the virus population, 320SI virus infec-
tion was first established in the permissive human T-cell leu-
kemia virus type 1 (HTLV-1)-transformed MT4 T-cell line
(25). Continued cocultivation of these 320SI-infected MT4 cell
cultures with FDA/H9 cells yielded immunofluorescence evi-
dence of infection of the FDA/H9 cells after 4 weeks, and a low
level of FDA/H9 cell infection was subsequently obtained on
passage of the culture supernatant onto naive FDA/H9 cells.
Complete and persistent infection of this culture was obtained
in an additional 3 weeks, and the TCLA virus produced was des-
ignated 320SI-C3. Subsequent low-multiplicity passages onto
fresh FDA/H9 cells yielded virus populations 320SI-C3.1
through -C3.3 over the course of 5 months. These TCLA vi-
ruses readily infect FDA/H9 and H9 cells and yield virus titers
comparable to those of prototypic TCLA viruses.
Coreceptor utilization by the pedigreed PI and TCLA vi-
ruses. Based on the SI phenotype of the parental 320SI virus,
we anticipated that this virus would utilize both CCR5 and
CXCR4 as coreceptors for infection. Similarly, we anticipated
that the TCLA 320SI-C3 virus would have lost the ability to
utilize CCR5, as all of the TCLA isolates analyzed to date uti-
lize CXCR4 but not CCR5 (1, 2, 6, 10, 12, 13, 27, 47). To assess
coreceptor utilization, cell culture supernatants of infected
PBLs (320SI) or FDA/H9 cells (320SI-C3) were titrated for
infectivity in U87 human glioma cells expressing CD4 and
either CCR5 or CXCR4 (23, 27). After 2 days of incubation,
cell monolayers were fixed with methanol-acetone and immu-
nochemically stained by using HIV/IG (38), an anti-human ABC
kit (Biomeda Corp.), and a diaminobenzamidine substrate.
Contrary to expectations based on other TCLA viruses, rel-
ative utilization of CCR5 and CXCR4 remained unchanged
upon adaptation (Fig. 1). The TCLA 320SI-C3 virus continued
to utilize CCR5, despite adaptation and growth in a T-cell line
that nominally does not express CCR5. Flow cytometric anal-
ysis using CCR5-directed monoclonal antibody (MAb) 2D7
(58) was able to detect CCR5 expression on PBLs and on the
PM-1 T-cell line (29) but was unable to detect its expression on
FDA/H9 cells (data not shown).
We wanted to confirm that this unique pattern of dual co-
receptor use by a TCLA virus was stable through additional
passage in FDA/H9 cells. We examined coreceptor utilization
by the repeatedly passaged 320SI-C3.3 virus. This virus was
also indistinguishable from the original PI virus 320SI in core-
ceptor specificity (Fig. 1). Thus, dual use of CCR5 and CXCR4
appears to be a stable property of the TCLA 320SI-C3 virus.
The adaptation procedure used here to obtain 320SI-C3 dif-
fers from that used previously to isolate a TCLA derivative of
another SI primary virus, ACH168.10 (50, 55). This biological
isolate was able to directly establish infection in the FDA/H9
cell line, albeit over the course of 4 to 12 weeks, without the
need for expansion in MT4 cells. Although expansion in per-
missive MT4 cells may have been important in generating
sequence diversity in the molecularly cloned 320SI virus pop-
ulation, it was also conceivable that this passage history af-
fected the adaptation process and coreceptor preference of the
ultimate TCLA virus.
To address this possibility, we repeated the adaptation of
ACH168.10 (168P) by using an MT4 cell line intermediate.
The 168M virus derived from the MT4 cell culture retained PI
virus phenotypes, including dual-coreceptor utilization and the
lack of measurable FDA/H9 cell tropism, as did the MT4 cell
line-expanded 320SI virus (data not shown). This observation
supports the contention that MT4 cells are permissive and
nonselective towards SI viruses, serving here simply to broaden
the quasispecies distribution of the molecularly cloned 320SI
virus. Following cocultivation and adaptation of 168M to per-
sistent growth in FDA/H9 cells, the newly derived TCLA virus
168MC2 lost the ability to utilize CCR5 (Fig. 2), as had the
original TCLA 168C virus that was directly adapted to growth
in FDA/H9 cells (27, 55). Thus, the retention of dual-corecep-
tor use by the TCLA 320SI-C3 virus is not a reflection of its
passage through MT4 cells prior to adaptation to growth in the
FDA/H9 cell line. Rather, different viruses appear to respond
differently to selection for growth in T-cell lines.
Neutralization sensitivity of the TCLA 320SI-C3 virus. Pre-
vious studies had demonstrated that adaptation to persistent
growth in established T-cell lines renders the TCLA virus sen-
sitive to neutralization by a broad range of reagents (33, 55).
Similarly, TCLA virus 320SI-C3 demonstrated de novo sensi-
tivity to V3-directed MAbs 50.1, 58.2, and 59.1 (Fig. 3a to c,
respectively) (54). The core epitopes of the latter two MAbs
have been mapped and are present in the known amino acid
sequence of 320SI (IGPGRAF and GPGRAF, respectively
[19, 54]); the core epitope of MAb 50.1 has also been deter-
mined crystallographically (RIHIG [39]) and differs from that
present in 320SI (GIHIG). The 320SI-C3 virus was also newly
sensitive to CD4 binding domain-directed MAb IgG1 b12 (5),
to CD4 immunoadhesin (CD4-Ig) (48), and to HIVIG (Fig. 3d
FIG. 1. Coreceptor utilization by pedigreed 320SI viruses. U87-CD4 cells expressing CCR5 (E) or CXCR4 (F) were infected with serial dilutions of the following
viruses: 320SI from PBL culture supernatant and 320SI-C3 and 320SI-C3.3 from FDA/H9 cell culture supernatant. Foci were quantitated 2 days later as described in
the text. Relative utilization of CCR5 and CXCR4 was judged by the relative titer on the respective coreceptor-expressing cells. Coreceptor-specific titer was determined
on the linear portion of the virus titration curve.
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to f, respectively). Thus, as in previous studies, increased sen-
sitivity to virus neutralization appeared coordinately with ad-
aptation to growth in established T-cell lines.
Because of the dual-coreceptor use by these PI and TCLA
viruses, we were able to investigate neutralization sensitivity as
a function of coreceptor use (Fig. 3). In all cases, neutralization
sensitivity was independent of the coreceptor utilized for in-
fection of U87-CD4 cells. We had previously demonstrated
this for PI virus ACH168.10 (27); we can now extend this con-
clusion to a TCLA virus. Furthermore, not only is neutraliza-
tion sensitivity independent of the process of utilizing a specific
coreceptor, it is also independent of the changes in coreceptor
specificity that often accompany adaptation to growth in T-cell
lines.
DNA sequence analysis of the 320SI-C3 envelope gene. In
our previous analysis of the adaptation of ACH168.10 (168P),
we defined three adaptation-associated amino acid changes
within the envelope protein of TCLA virus 168C: I166R in V2,
I282N in C2, and G318R in V3 (55). For the present study, we
wished to determine whether similar amino acid changes had
arisen during adaptation of the 320SI virus. Proviral DNA
from FDA/H9 cells infected with 320SI-C3 was amplified by
using envelope-specific primers (envA and envN [18]) and
high-fidelity XL PCR (PE Applied Biosystems) (27), and the
FIG. 2. Coreceptor utilization by TCLA virus 168MC2 adapted through an MT4 cell line intermediate. U87-CD4 cells expressing CCR5 (E) or CXCR4 (F) were
infected with serial dilutions of the following viruses: 168P from PBL culture supernatant (27, 55), 168MC2 from FDA/H9 cell culture supernatant following expansion
in an MT4 cell culture, and 168C from FDA/H9 cell culture supernatant following direct adaptation to FDA/H9 cells (27, 55).
FIG. 3. Neutralization sensitivity of 320SI (PI) and 320SI-C3 (TCLA) in U87-CD4 cell lines expressing the CCR5 or CXCR4 coreceptor. Virus stocks of 320SI (E,
F) and 320SI-C3 (h, ■) comprising cell culture supernatants (from PBLs and FDA/H9 cells, respectively) were standardized to yield a submaximal number of foci of
infection on U87-CD4-CCR5 (E, h) or U87-CD4-CXCR4 (F, ■) cells. The virus was incubated with the indicated reagents for 1 h prior to infection (a to f).
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DNA sequence of the envelope gene was compared with those
of ACH320.2A.1.2 (22) and 320SI. Two amino acid changes in
gp120 were noted (I166K and H317R (GenBank accession
no. AF069524). The I166K change in the V2 region is sim-
ilar to the I166R change in the unrelated 168C envelope.
We do not know whether the change is fortuitous or whether
this common amino acid change points to a common func-
tion. The H317R change is located within the crown of the V3
loop (KGIHIGPGRAF to KGIRIGPGRAF) but distant from
the G318R change in the 168C envelope (GRAFYTTRQII).
The increased positive charge in the V3 loop is consistent with
similar trends in other PI and TCLA viruses (9, 17, 55). In the
case of the 320SI-C3 virus, however, the increased positive
charge may be associated with adaptation and neutralization
sensitivity but is not associated with altered coreceptor use.
In summary, our finding of this unique TCLA virus that is
now sensitive to neutralization but continues to utilize both
CCR5 and CXCR4 extends our earlier observations divorcing
coreceptor utilization and sensitivity to neutralization. Not
only are PI viruses resistant to neutralization regardless of
whether CCR5 or CXCR4 is used in infection, but changes in
the ability to utilize these coreceptors are not required for the
acquisition of neutralization sensitivity in the TCLA virus. Fur-
thermore, the TCLA virus remains sensitive to neutralization
regardless of the coreceptor utilized for infection.
Our findings also divorce changes in coreceptor utilization
and adaptation to growth in established T-cell lines. Clearly,
the often-observed loss of the ability of TCLA viruses to utilize
CCR5 is not necessary for adaptation. It is possible, however,
that adaptation might derive from more subtle changes in the
virus’s interaction with CXCR4. Initial studies to examine the
sensitivity to inhibition by the CXCR4 ligand SDF-1 (4, 34),
however, did not yield a consistent pattern: whereas 320SI-C3
showed increased sensitivity to inhibition by SDF-1, 168C
showed decreased sensitivity (data not shown). Thus, the
relationship between coreceptor utilization and adaptation
to growth in T-cell lines remains elusive. Appropriate corecep-
tor expression may be necessary for infection, but it is by no
means sufficient, as restrictions to productive infection can
exist at multiple levels in the viral life cycle (16, 59, 60).
Our observations that these phenotypically distinct viruses
can continue to utilize both coreceptors and that the capacity
to utilize CCR5 is retained despite the apparent lack of the
CCR5 coreceptor on FDA/H9 cells suggest that the structural
requirements for specific coreceptor binding are relatively min-
imal. In fact, multiple studies to define critical sites for enve-
lope-coreceptor interaction have not yielded entirely consis-
tent generalizations (3, 11, 26, 35, 36, 40, 41, 49). The variable
and diffuse nature of functional envelope-coreceptor pairings
is consistent with an interaction surface comprising multiple
weak contacts. We suggest that the free energy of coreceptor
binding may derive in part from the entropic contribution of
the initial binding to CD4 in localizing the envelope-corecep-
tor interaction to two dimensions. Subsequent interactions are
driven both by conformational changes induced within the
envelope protein complex upon CD4 binding (51, 57) and by
proximity on the membrane but ultimately involve multiple
weak contacts over a variable surface of envelope-coreceptor
interaction. The observed relationship between infectivity by
PI viruses and cell surface CD4 density is consistent with this
model (24).
In certain instances, the entropic contributions of CD4 bind-
ing may be less significant to the overall free energy of enve-
lope protein binding, as in certain human and simian immu-
nodeficiency virus isolates that are able to interact directly with
a coreceptor to allow CD4-independent infection (14, 15, 30).
This capability may derive from an envelope protein confor-
mation that more closely approximates that induced by CD4
binding, or perhaps from other enhancements in the envelope-
coreceptor interaction.
To the extent that the envelope-coreceptor interaction is
diffuse and that specificity is determined by the sum of many
weak contacts, the effects of specific changes in either protein
on overall binding may not be readily predictable. The changes
in the 320SI-C3 envelope protein that determine cell tropism
appear not to perturb significantly the envelope-CCR5 binding
surface, whereas those in the 168C envelope protein preclude
effective interaction. Perhaps subtle changes in envelope-core-
ceptor interaction underlie the observed changes in cell tro-
pism and neutralization sensitivity that define adaptation. At
the current level of analysis, however, these fundamental viral
phenotypes appear to be independent of specific coreceptor
utilization.
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